Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 64

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 64
---
     | Fees Earned 
 or Paid in  
 Cash ($)    |        |     | Option    
 Awards    
 ($)(1)(2) |         |     | Total ($) |         |
| Paul B. Manning      |     |             |      — |     |           |       — |     |           |       — |
| Mark Prygocki        |     |             | 70,000 |     |           | 131,900 |     |           | 201,900 |
| Sean Stalfort        |     |             |      — |     |           |       — |     |           |       — |
| Diem Nguyen          |     |             | 40,000 |     |           | 131,900 |     |           | 171,900 |
| Lawrence Eichenfield |     |             | 60,000 |     |           | 131,900 |     |           | 191,900 |
| Craig Ballaron(3)    |     |             | 48,750 |     |           | 131,900 |     |           | 180,650 |

| (1) | The amounts reported do not reflect the amounts actually received by our non-employee directors. Instead, these amounts reflect the aggregate grant date fair value of each stock option granted to our non-employee directors during the fiscal year ended December 31, 2024, as computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based compensation transactions (ASC 718). Assumptions used in the calculation of these amounts are included in Note 8 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. Our non-employee directors who have received options will only realize compensation with regard to these options to the extent the trading price of our common stock is greater than the exercise price of such options. |

| (2) | As of December 31, 2024, Mr. Prygocki, Dr. Nguyen, Dr. Eichenfield and Mr. Ballaron held options to purchase 78,047 shares, 66,379 shares, 68,379 and 57,213 shares of our common stock, respectively. None of our other non-employee directors held options to purchase shares of our common stock as of December